Novavax (NVAX) Accounts Payables (2010 - 2026)

Novavax's Accounts Payables history runs 17 years deep, the most recent figure standing at $16.1 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 52.87% year-over-year to $16.1 million; the TTM figure through Mar 2026 stood at $16.1 million (down 52.87% YoY), while the FY2025 annual figure was $24.6 million, down 40.89% from the prior year.
• Accounts Payables was $16.1 million for Q1 2026 at Novavax, down from $24.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $386.5 million in Q2 2022 to a low of $15.2 million in Q3 2025.
• Historically, Accounts Payables has averaged $100.4 million across 5 years, with a median of $80.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables soared 422.32% in 2022, then slumped 77.43% in 2023.
• A 5-year view of Accounts Payables shows it stood at $216.5 million in 2022, then sank by 38.75% to $132.6 million in 2023, then plunged by 68.65% to $41.6 million in 2024, then slumped by 40.89% to $24.6 million in 2025, then sank by 34.49% to $16.1 million in 2026.
• The last three Accounts Payables figures came in at $16.1 million (Q1 2026), $24.6 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.